SCHEMBL2899508

SCHEMBL2899508

Cc1nnc(C2CCN(C(=O)OC(C)(C)C)CC2)[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MAPT P10636 1/20 0.51
HPGDS O60760 2/20 0.50
GPR119 Q8TDV5 5/20 0.48
HPGD P15428 1/20 0.45
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44
TYK2 P29597 1/20 0.44
JAK3 P52333 1/20 0.44
HTT P42858 1/20 0.44
RECQL P46063 1/20 0.43
EPHX1 P07099 1/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPN6 P29350 1/20 0.42
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18788548 0.93 THRB (0.46) THRBKDM4EMAPTHPGDSGPR119
SCHEMBL947009 0.80 KDM4E (0.53) THRBKDM4EMAPTHPGDSGPR119
SCHEMBL4343857 0.80 HPGDS (0.55) THRBKDM4EMAPTHPGDSGPR119
SCHEMBL17464841 0.80 ALDH1A1 (0.43) THRBKDM4EMAPTGPR119KMT2A
SCHEMBL3879923 0.79 HPGDS (0.62) THRBKDM4EMAPTHPGDSGPR119
SCHEMBL459905 0.78 MAPT (0.51) THRBKDM4EMAPTHPGDSGPR119
SCHEMBL17069042 0.78 ALDH1A1 (0.50) MAPTHTTKMT2A
SCHEMBL15556094 0.78 KDM4E (0.51) THRBKDM4EMAPTHPGDSGPR119
SCHEMBL17065213 0.78 HPGDS (0.50) THRBKDM4EMAPTHPGDSJAK2
SCHEMBL1662358 0.77 KDM4E (0.50) THRBKDM4EMAPTHPGDSGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010506-B1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2010-08-04 EP disclosed
US-7632829-B2 Diazepan derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-15 US disclosed
EP-2010506-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-Roche AG (CH) 2009-01-07 EP disclosed
WO-2007122103-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-01 WO disclosed
US-20070249589-A1 Novel diazepan derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249589-A1 Novel diazepan derivatives CCR3, CCR1, CCR10 THRB 1804/4885KDM4E 3080/4885MAPT 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.